Cargando…

Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future

SIMPLE SUMMARY: Gliomas are aggressive central nervous system tumours. The emergence and recent widespread adoption of 5-aminolevulinic acid and fluorescence guided surgery have improved the extent of resection, with implications for improved survival and progression-free survival. This review descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Rosa, Cuthbert, Hadleigh, Watts, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304525/
https://www.ncbi.nlm.nih.gov/pubmed/34298721
http://dx.doi.org/10.3390/cancers13143508
_version_ 1783727356732506112
author Sun, Rosa
Cuthbert, Hadleigh
Watts, Colin
author_facet Sun, Rosa
Cuthbert, Hadleigh
Watts, Colin
author_sort Sun, Rosa
collection PubMed
description SIMPLE SUMMARY: Gliomas are aggressive central nervous system tumours. The emergence and recent widespread adoption of 5-aminolevulinic acid and fluorescence guided surgery have improved the extent of resection, with implications for improved survival and progression-free survival. This review describes the history, rationale and mechanism behind the use of 5-aminolevulinic acid and fluorescence-guided surgery. We also discuss current limitations and future directions for this important adjunct to glioma surgery. This review aims to provide readers with an up-to-date overview and evidence base on this important topic. ABSTRACT: Gliomas are central nervous systems tumours which are diffusely infiltrative and difficult to treat. The extent of surgical resection is correlated with improved outcomes, including survival and disease-free progression. Cancerous tissue can be directly visualised intra-operatively under fluorescence by administration of 5-aminolevulinic acid to the patient. The adoption of this technique has allowed surgeons worldwide to achieve greater extents of resection, with implications for improved prognosis. However, there are practical limitations to use of 5-aminolevulinic acid. New adjuncts in the field of fluorescence-guided surgery aim to improve recognition of the interface between tumour and brain with the objective of improving resection and patient outcomes.
format Online
Article
Text
id pubmed-8304525
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83045252021-07-25 Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future Sun, Rosa Cuthbert, Hadleigh Watts, Colin Cancers (Basel) Review SIMPLE SUMMARY: Gliomas are aggressive central nervous system tumours. The emergence and recent widespread adoption of 5-aminolevulinic acid and fluorescence guided surgery have improved the extent of resection, with implications for improved survival and progression-free survival. This review describes the history, rationale and mechanism behind the use of 5-aminolevulinic acid and fluorescence-guided surgery. We also discuss current limitations and future directions for this important adjunct to glioma surgery. This review aims to provide readers with an up-to-date overview and evidence base on this important topic. ABSTRACT: Gliomas are central nervous systems tumours which are diffusely infiltrative and difficult to treat. The extent of surgical resection is correlated with improved outcomes, including survival and disease-free progression. Cancerous tissue can be directly visualised intra-operatively under fluorescence by administration of 5-aminolevulinic acid to the patient. The adoption of this technique has allowed surgeons worldwide to achieve greater extents of resection, with implications for improved prognosis. However, there are practical limitations to use of 5-aminolevulinic acid. New adjuncts in the field of fluorescence-guided surgery aim to improve recognition of the interface between tumour and brain with the objective of improving resection and patient outcomes. MDPI 2021-07-13 /pmc/articles/PMC8304525/ /pubmed/34298721 http://dx.doi.org/10.3390/cancers13143508 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sun, Rosa
Cuthbert, Hadleigh
Watts, Colin
Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future
title Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future
title_full Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future
title_fullStr Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future
title_full_unstemmed Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future
title_short Fluorescence-Guided Surgery in the Surgical Treatment of Gliomas: Past, Present and Future
title_sort fluorescence-guided surgery in the surgical treatment of gliomas: past, present and future
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304525/
https://www.ncbi.nlm.nih.gov/pubmed/34298721
http://dx.doi.org/10.3390/cancers13143508
work_keys_str_mv AT sunrosa fluorescenceguidedsurgeryinthesurgicaltreatmentofgliomaspastpresentandfuture
AT cuthberthadleigh fluorescenceguidedsurgeryinthesurgicaltreatmentofgliomaspastpresentandfuture
AT wattscolin fluorescenceguidedsurgeryinthesurgicaltreatmentofgliomaspastpresentandfuture